STOCK TITAN

Crinetics Pharmaceuticals - CRNX STOCK NEWS

Welcome to our dedicated page for Crinetics Pharmaceuticals news (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals stock.

Crinetics Pharmaceuticals (CRNX) is a clinical-stage biopharmaceutical company pioneering oral therapies for endocrine disorders and related tumors. This news hub provides investors and industry professionals with timely updates on clinical trial progress, regulatory milestones, and corporate developments.

Access official press releases, financial reports, and scientific updates related to CRNX's lead candidates: paltusotine for acromegaly/carcinoid syndrome and atumelnant targeting adrenal disorders. Our curated news collection enables efficient tracking of therapeutic innovations in rare diseases, partnership announcements, and market-moving events.

Content spans clinical data publications, FDA communications, executive leadership updates, and research collaborations. Bookmark this page for direct access to primary-source information about CRNX's novel small molecule therapies and their development pathways.

Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. will participate in a fireside chat and investor meetings at the Cantor Global Healthcare Conference in New York City on September 26-28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
conferences
-
Rhea-AI Summary
Crinetics Pharmaceuticals announces pricing of upsized public offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.7%
Tags
-
Rhea-AI Summary
Crinetics Pharmaceuticals plans to offer $250.0 million of common stock in a public offering, with an option for underwriters to purchase an additional $37.5 million. Proceeds will fund the development of paltusotine, CRN04894, and other R&D programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.29%
Tags
Rhea-AI Summary
Crinetics Pharmaceuticals grants non-qualified stock options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
63.31%
Tags
none
-
Rhea-AI Summary
Crinetics Pharmaceuticals announces positive results from Phase 3 PATHFNDR-1 study for paltusotine in acromegaly patients. 83% of participants maintained IGF-1 ≤1.0 xULN vs. 4% on placebo. Mean IGF-1 levels and symptom diary scores were maintained. Paltusotine was well-tolerated with no severe or serious adverse events. Conference call scheduled for September 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. reported financial results for Q2 2023. The company expects to release topline data from its Phase 3 PATHFNDR-1 study in September 2023, providing insight into paltusotine's potential as an alternative treatment for acromegaly. Enrollment in the Phase 3 PATHFNDR-2 study is complete, with topline results expected in Q1 2024. However, the company has suspended development of its CRN04777 program due to nonclinical profile concerns. Crinetics plans to submit a new drug application for paltusotine in acromegaly in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) will host a Key Opinion Leader (KOL) webinar featuring presentations by KOLs Beverly MK Biller M.D. and Karen JP Liebert, R.N., BSN, both of Massachusetts General Hospital. They will discuss the current landscape and unmet medical need in acromegaly, as well as the treatment burden associated with standard-of-care injectable somatostatin receptor ligands (SRLs). The Crinetics management team will also discuss its pipeline of internally discovered oral small molecule drug candidates, with a focus on the Phase 3 PATHFNDR-1 study of paltusotine, an investigational, once-daily oral small molecule somatostatin receptor type 2 agonist.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
none
Crinetics Pharmaceuticals

Nasdaq:CRNX

CRNX Rankings

CRNX Stock Data

2.83B
90.46M
2.09%
110.85%
8.71%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO